Binds Enzyme Patents (Class 530/388.26)
  • Patent number: 9783795
    Abstract: Peptides of from about 7 to about 50 amino acid residues in length that have epitopes that bind to more than one HLA class II protein and stimulate CD4+ T cells for treatment of cancer from one of three serine proteases overexpressed in ovarian cancer and other cancers—stratum corneum chymotryptic enzyme, matriptase, and hepsin—are described. Since the peptides bind to more than one HLA class II protein variant, they can be used to treat cancer in most patients of a population having a variety of HLA class II alleles. The peptides can be loaded onto autologous dendritic cells of a cancer patient and infused into the patient to activate a CD4+ and CD8+ T cell response that recognizes tumor cells expressing the peptide antigen.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: October 10, 2017
    Inventors: Martin J. Cannon, Kristina L. Bondurant, Timothy J. O'Brien
  • Patent number: 9758810
    Abstract: Provided herein are methods for identifying centromeres and centromeres identified by such methods. Centromeres of organisms such as algae, fungi, and protists can be used, for example, for constructing artificial chromosomes and cells containing such artificial chromosomes.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: September 12, 2017
    Assignee: Synthetic Genomics, Inc.
    Inventors: Helge Zieler, Robert Christopher Brown, Toby Howard Richardson, Douglas Gillette Smith
  • Patent number: 9428586
    Abstract: The present invention, in at least some aspects, is of splice variants of heparanase, as well as diagnostic kits and methods of use, and therapeutic agents and methods of use based thereon, and antibodies specifically binding thereof.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: August 30, 2016
    Assignee: COMPUGEN LTD
    Inventors: Ronen Shemesh, Michal Ayalon-Soffer, Zurit Levine, Sergey Nemzer, Tomer Zekharya, Gad S. Cojocaru, Uri Barash, Neta Ilan, Israel Vlodavsky, Iris Hecht
  • Patent number: 9074002
    Abstract: Described herein are agents, including antibodies, antibody fragments, polypeptides and organic small molecules, that bind reversibly inactive PTP1B (designated herein in the alternative as PTP1B-SN or PTP1B-OX) and stabilize it (stabilize PTP1B-OX) in such a manner that they inhibit reactivation of reversibly oxidized, inactive PTP1B by reduction (by reducing agent) and have no substantial direct inhibitory effect on phosphatase activity/PTP1B activity (for example, as detectable in assays in vitro).
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: July 7, 2015
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Nicholas Tonks, Aftabul Haque
  • Publication number: 20150140005
    Abstract: There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 21, 2015
    Inventors: Keith R. Walley, John H. Boyd, James A. Russell
  • Patent number: 9029515
    Abstract: The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5). In other words, the KD or koff ratio at pH 5.5/pH 7.4 or at pH 6.0/pH 7.4 is more than, or ranges between, 2, 3, 4, 8, 10, 16, 20, 30, 40, or 100 or more. Such pH dependent antibodies preferentially dissociate from the antigen in the endosome. This can increase antibody half life, as compared to antibodies with equivalent KDs at pH 7.4 but with no pH dependent binding, when the antigen is one that undergoes antigen-mediated clearance (e.g., PCSK9). Antibodies with pH dependent binding can decrease total antigen half life when the antigen undergoes reduced clearance when bound to antibody (e.g., IL6). Antibodies with pH dependent binding can also prolong the decrease in antigen which is not antibody-bound.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: May 12, 2015
    Assignees: Rinat Neuroscience Corp., Pfizer Inc.
    Inventors: Jaume Pons, Jeffrey Raymond Chabot, Javier Fernando Chaparro Riggers, Bruce Charles Gomes, Hong Liang, Kapil Mayawala, Jerome Thomas Mettetal, II, Arvind Rajpal, David Louis Shelton
  • Patent number: 9017957
    Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: April 28, 2015
    Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro Kitamura
    Inventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
  • Patent number: 9000134
    Abstract: The invention provides reagents and methods for diagnosing kidney disease in a human or animal.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: April 7, 2015
    Inventors: Wallace B. Haigh, Donald L. Very, Jr.
  • Patent number: 9000132
    Abstract: The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: April 7, 2015
    Assignee: diaDexus, Inc.
    Inventors: Paul Levi Miller, Laura Corral
  • Publication number: 20150087812
    Abstract: Antibodies and compositions capable of binding and, in a particular aspect, inhibiting the lysophosphatidylipase D activity of human autotaxin protein. The antibodies or are useful in detecting human autotaxin protein and treating diseases and disorders associated with unwanted lysophosphatidylipase D and the presence of lysophosphatidic acid, such as cancer and pulmonary diseases.
    Type: Application
    Filed: March 11, 2013
    Publication date: March 26, 2015
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Ellen Chi, Thai Dinh, Suzanne Edavettal, Sandra Fenton, Damon Hamel, Sheri Moores, Jose Pardinas, H. Mimi Zhou, Barry L. Ziober
  • Patent number: 8981064
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: March 17, 2015
    Assignee: Amgen Inc.
    Inventors: Simon Mark Jackson, Bei Shan, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
  • Patent number: 8956614
    Abstract: The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: February 17, 2015
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Bart De Strooper, Lujia Zhou, Wim Annaert
  • Publication number: 20150044226
    Abstract: A monoclonal antibody that binds to a phospholipase D4 (PLD4) protein, or a fragment containing an antigen-binding region thereof.
    Type: Application
    Filed: January 31, 2013
    Publication date: February 12, 2015
    Applicant: SBI Biotech Co., Ltd
    Inventors: Minkwon Cho, Tomohide Yamazaki, Mayuki Endo, Koji Ishida
  • Patent number: 8933202
    Abstract: The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: January 13, 2015
    Assignee: U3 Pharma GmbH
    Inventors: Thore Hettmann, Jens Niewöhner, Jens Ruhe, Peter Wirtz, Kerstin Selle, Esther Zwick-Wallasch, Mike Rothe
  • Patent number: 8927220
    Abstract: A protein used as a biomarker for diagnosing IgA nephropathy and TGBM (thin-glomerular-basement-membrane) using urine through a target proteomics method. A diagnosis biomarker protein and a kit for diagnosing IgA nephropathy and TGBM and predicting progress of the nephropathy in advance using the protein are provided. The degree of the progression of the disease can be grasped by detecting IgA nephropathy and TGBM, enabling early diagnosis and confirming progress from the patient's urine. In addition, a monoclonal antibody produced based on the diagnosis biomarker protein can be used for an immunoassay kit (ELISA, antibody coated tube test, lateral-flow test, potable biosensor). The monoclonal antibody is used in early diagnosis and progression detection of IgA nephropathy and development of a novel drug for the purpose of treatment.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: January 6, 2015
    Assignee: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Moon Chang Baek, Pyong Gon Moon, Yong Lim Kim
  • Patent number: 8927225
    Abstract: Disclosed is an assay (method) to quantify the amounts of catecholamine-O-methyltransferase (COMT) protein in samples, such as extracts from cell cultures, body fluids, tissues, and environmental samples. It uses novel agents (anti-NE, COMT-NE, or COMT-epitope-NE) in combination with two previously described agents (anti-COMT and COMT) in a competitive ELISA system to achieve this aim.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: January 6, 2015
    Assignee: The University of Hong Kong
    Inventors: Shu Leong Ho, Wing Lok Ho, David Boyer Ramsden
  • Patent number: 8916154
    Abstract: Disclosed are antibodies that specifically recognize ?5-desaturase, methods of producing the antibodies, nucleotides and polypeptides for producing the antibodies, and methods of using the antibodies. The ?5-desaturase-specific antibodies provide improved methods of detecting ?5-desaturase in a sample.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: December 23, 2014
    Assignee: Abbott Laboratories
    Inventors: Tapas Das, Suzette L. Pereira, Pradip Mukerji, Padmavathy Krishnan
  • Publication number: 20140348850
    Abstract: The present invention relates to methods of reducing blood pressure in a subject by administering a plasma kallikrein inhibitor.
    Type: Application
    Filed: August 15, 2014
    Publication date: November 27, 2014
    Inventors: Edward P. Feener, Allen Clermont
  • Publication number: 20140341927
    Abstract: The present invention concerns an antibody which specifically binds to an abnormal superoxide dismutase 1 (SOD1), and which neutralizes its pathologic effect when administered to an animal such as a human. The antibody of the invention is a monoclonal antibody produced by hybridoma cell lines deposited with the International Depositary Authority of Canada on Aug. 29, 2006 under accession numbers ADI-290806-01, ADI-290806-02 and ADS-290806-03. The present invention also concerns the use of the antibody of the invention in the treatment, prevention and diagnosis of neurodegenerative diseases such as Amyotrophic lateral sclerosis, Parkinson and Alzheimer in an animal such as a human.
    Type: Application
    Filed: May 27, 2014
    Publication date: November 20, 2014
    Applicant: Universite Laval
    Inventors: Jean-Pierre Julien, Makoto Urushitani
  • Patent number: 8889834
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: November 18, 2014
    Assignee: Amgen Inc.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
  • Patent number: 8883983
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: November 11, 2014
    Assignee: Amgen Inc.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
  • Patent number: 8883154
    Abstract: The present invention is drawn to antibody-mediated modulation of allergy. In this regard, the present invention discloses a monoclonal antibody, antigen-binding fragment or mimic thereof directed against Group 1 pollen allergens or homologues thereof. Also disclosed herein is the mechanism by which the disclosed monoclonal antibody, antigen binding fragment or mimic thereof will improve immunotherapy of allergic reactions in an individual. It is contemplated that herein that such a monoclonal antibody, antigen binding fragment or mimic thereof may also be useful in treatment of several microbial infections.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: November 11, 2014
    Assignee: The Board of Regents of the University of Texas Systems
    Inventors: Randall M. Goldblum, Terumi Midoro-Horiuti, Bo Ning, Ruby Tiwari
  • Publication number: 20140329253
    Abstract: A monoclonal antibody that binds specifically to the SNAP motif and to the CLIP tag comprising CDRs with the amino acid sequences SEQ ID Nos. 3, 4, 5, and 8, 9, 10.
    Type: Application
    Filed: November 26, 2012
    Publication date: November 6, 2014
    Applicant: Fraunhofer-Gesllschaft zur Foerderung der angewandten Forschung e.V.
    Inventors: Stefan Barth, Katharina Kolberg, Christiane Püttmann, Severin Schmies
  • Patent number: 8877900
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: November 4, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Peter Peizhi Luo, Kevin Caili Wangr, Pingyu Zhong, Mark Hsieh, Yan Li, Xinwei Wang, Feng Dong, Andrei Golosov, Yan Ni, Weirong Wang, Laurence B. Peterson, Rose Cubbon, Sujata Sharma, Jon Condra, Jun Lu, Gopalakrishnan Parthasarathy, Stephen Soisson, Noel Byrne
  • Publication number: 20140322726
    Abstract: It is an object of the present invention to provide a monoclonal antibody, which is suitable for the quantitative analysis of asparagine synthetase in a cell. The present invention provides a monoclonal antibody which specifically recognizes asparagine synthetase that is present in a cell.
    Type: Application
    Filed: October 3, 2012
    Publication date: October 30, 2014
    Inventors: Takao Hamakubo, Yasuhiro Mochizuki, Hiroko Iwanari, Osamu Arai, Toshiyuki Kitoh, Masahito Tsurusawa
  • Patent number: 8871914
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: October 28, 2014
    Assignee: Amgen, Inc.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
  • Patent number: 8871913
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: October 28, 2014
    Assignee: Amgen Inc.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
  • Patent number: 8859741
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: October 14, 2014
    Assignee: Amgen Inc.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Wenyan Shen, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo
  • Publication number: 20140286963
    Abstract: The invention provides antibodies to specific neural proteins and methods of using the same.
    Type: Application
    Filed: May 30, 2014
    Publication date: September 25, 2014
    Applicant: GENENTECH, INC.
    Inventors: Jasvinder Atwal, Yongmei Chen, Cecilia Pui Chi Chiu, Robert A. Lazarus, Weiru Wang, Ryan J. Watts, Yan Wu, Yingnan Zhang
  • Patent number: 8841108
    Abstract: A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: September 23, 2014
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Irit Sagi, Tamar Danon
  • Patent number: 8841424
    Abstract: The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: September 23, 2014
    Assignee: U3 Pharma GmbH
    Inventors: Peter Wirtz, Jens Ruhe, Takeshi Takizawa, Tomoko Takayama
  • Patent number: 8841423
    Abstract: Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: September 23, 2014
    Assignee: University of Iowa Research Foundation
    Inventors: Mark E. Anderson, Peter J. Mohler, Douglas R. Spitz, Jr., Jeffrey Robert Erickson
  • Publication number: 20140283157
    Abstract: The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: diaDexus, Inc.
    Inventors: Paul Levi Miller, Laura Corral
  • Publication number: 20140275485
    Abstract: The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.
    Type: Application
    Filed: July 31, 2013
    Publication date: September 18, 2014
    Applicant: diaDexus, Inc.
    Inventors: Paul Levi MILLER, Laura CORRAL
  • Patent number: 8834874
    Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in iduronate 2-sulfatase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody that crosses the blood brain barrier (BBB) and an iduronate 2-sulfatase.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: September 16, 2014
    Assignee: ArmaGen Technologies, Inc.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 8821874
    Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: September 2, 2014
    Assignee: Allergan, Inc.
    Inventors: Michael E. Stern, Christopher S. Schaumburg, Karyn F. Siemasko, Jianping Gao
  • Publication number: 20140228545
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Application
    Filed: April 24, 2014
    Publication date: August 14, 2014
    Applicant: Amgen, Inc.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Joyce Chi Yee Chan, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo, Qiong Cao
  • Publication number: 20140228547
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Application
    Filed: April 24, 2014
    Publication date: August 14, 2014
    Applicant: Amgen, Inc.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Joyce Chi Yee Chan, Chadwick Terence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo, Qiong Cao
  • Patent number: 8802827
    Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: August 12, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Peter Peizhi Luo, Kevin Caili Wang, Pingyu Zhong, Mark Hsieh, Yan Li, Xinwei Wang, Feng Dong, Andrei Golosov, Yan Ni, Weirong Wang, Laurence B. Peterson, Rose Cubbon
  • Patent number: 8796428
    Abstract: The invention relates to an antibody specific to Erk1/2 phosphorylated at Thr188 and a method for producing the same. The invention also relates to an in vitro method for determining the presence of phosphorylated Erk1/2 in a sample using the antibody of the invention. Therefore, the invention also comprises an assay for diagnosing a heart disease in vitro comprising the antibody of the invention and certain uses of the antibody. Moreover the invention relates to a peptide used to produce the antibody.
    Type: Grant
    Filed: November 26, 2009
    Date of Patent: August 5, 2014
    Assignee: Julius-Maximilians-Universitaet Wuerzburg
    Inventors: Martin J. Lohse, Kristina Lorenz
  • Patent number: 8779106
    Abstract: Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: July 15, 2014
    Assignee: Incyte Corporation
    Inventors: Vicki S. Elliott, Reena Khare, Thomas W. Richardson, Joseph P. Marquis, Anita Swarnakar, April J. A. Hafalia, Shanya D. Becha, Narinder K. Chawla-Walia, Mariah R. Baughn, Soo Yeun Lee, Uyen K. Tran, Henry Yue, Danniel B. Nguyen, Michael B. Thornton, Rajagopal Gururajan, Ameena R. Gandhi, Yan Lu, Monique G. Yao, Joana X. Li, Wen Luo, Ernestine A. Lee, Ian J. Forsythe, Craig H. Ison, Amy D. Wilson, Pei Jin
  • Patent number: 8778885
    Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: July 15, 2014
    Assignee: Amorfix Life Sciences Ltd.
    Inventors: Neil R. Cashman, Avijit Chakrabartty, Rishi Rakhit, Joachim Bernhard Ostermann
  • Patent number: 8772459
    Abstract: In one embodiment, a minibody monomer that binds PSMA is provided. The minibody monomer is encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA, an artificial hinge sequence, and a human IgG CH3 sequence. In another embodiment, a CysDB monomer that binds PSMA is provided. The CysDB monomer may be encoded by a nucleotide sequence comprising, from N-terminus to C-terminus, an scFv sequence that can bind PSMA and a cysteine tail. In other embodiments, methods for diagnosing or treating a cancer associated with PSMA expression in a subject are provided.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: July 8, 2014
    Assignee: ImaginAb, Inc.
    Inventors: David Ho, Tove Olafsen, Arye Lipman
  • Publication number: 20140154699
    Abstract: The present invention relates to monoclonal antibodies which specifically recognize human liver-carboxylesterase 1, hybridoma cell lines which produce monoclonal antibodies, and uses thereof. The invention can be used for the objective analysis of the expression amount of human liver-carboxylesterase 1 in tissues and blood, and the like, by being specifically bound to the human liver-carboxylesterase 1. Therefore, liver cancer can be conveniently and quickly diagnosed from urine or blood.
    Type: Application
    Filed: April 17, 2012
    Publication date: June 5, 2014
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Young Ki Paik, Keun Na
  • Patent number: 8729239
    Abstract: The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: May 20, 2014
    Assignee: Nuclea Biotechnologies, Inc.
    Inventor: Patrick J. Muraca
  • Publication number: 20140127190
    Abstract: Described herein are peptides from secretory phospholipase A2-IB and antibodies that can be used to reduce the contribution of the gastrointestinal tract to inflammatory processes including systemic inflammatory responses. Specifically, antibodies that bind specifically a peptide from secretory phospholipase A2-IB prevent death in a mouse model of LPS-induced endotoxemia. The antibodies described herein are particularly useful to treat systemic inflammatory response syndromes, including sepsis.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 8, 2014
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Jordan Marshall Sand, Mark Eric Cook, Daniel Elmer Butz
  • Patent number: 8715658
    Abstract: The present invention is directed to a method of treating a subject at risk for or having a condition mediated by an inflammatory cytokine cascade comprising administering to the subject an amount of a GAPDH inhibitor effective to treat the subject at risk for or having a condition mediated by an inflammatory cytokine cascade.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: May 6, 2014
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin Tracey, William Parrish
  • Patent number: 8715672
    Abstract: The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and for preventing the formation and/or the stabilization of three dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: May 6, 2014
    Assignee: CSL Behring GmbH
    Inventors: Bernhard Nieswandt, Thomas Renne
  • Patent number: 8710192
    Abstract: The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a (“PCSK9”) and methods of using such antibodies.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: April 29, 2014
    Assignees: IRM LLC, Novartis AG
    Inventors: Sarah Rue, Steve B. Cohen, Jun Li, David Yowe
  • Patent number: 8697078
    Abstract: The present application relates to antibodies which recognize [2(2-aminoethylcarbomoyl)-ethoxymethyl]-tris-[2-N-(3-imidazol-1-yl-propyl))-ethoxymethyl]methane, a hapten molecule which closely mimics the local structure and conformation of the reactive zinc site in matrix metalloproteinases. An antibody is disclosed which comprises an antigen recognition region which comprises six CDR amino acid sequences selected from the group consisting of SEQ ID NOs: 4-15. Uses thereof are also disclosed.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: April 15, 2014
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Irit Sagi, Netta Sela-Paswell, Tamar Danon, Raanan Margalit